N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia.
Int J Mol Sci. 2023 Oct 16;24(20):15211. doi: 10.3390/ijms242015211.
T cells are crucial players in adaptive anti-cancer immunity. The gene modification of T cells with tumor antigen-specific T cell receptors (TCRs) was a milestone in personalized cancer immunotherapy. TCR is a heterodimer (either α/β or γ/δ) able to recognize a peptide antigen in a complex with self-MHC molecules. Although traditional concepts assume that an α- and β-chain contribute equally to antigen recognition, mounting data reveal that certain receptors possess chain centricity, i.e., one hemi-chain TCR dominates antigen recognition and dictates its specificity. Chain-centric TCRs are currently poorly understood in terms of their origin and the functional T cell subsets that express them. In addition, the ratio of α- and β-chain-centric TCRs, as well as the exact proportion of chain-centric TCRs in the native repertoire, is generally still unknown today. In this review, we provide a retrospective analysis of studies that evidence chain-centric TCRs, propose patterns of their generation, and discuss the potential applications of such receptors in T cell gene modification for adoptive cancer immunotherapy.
T 细胞是适应性抗肿瘤免疫的关键参与者。用肿瘤抗原特异性 T 细胞受体 (TCR) 对 T 细胞进行基因修饰是个性化癌症免疫治疗的一个里程碑。TCR 是一种异二聚体(α/β 或 γ/δ),能够识别与自身 MHC 分子结合的肽抗原。尽管传统观念认为 α 和 β 链对半抗原识别的贡献相等,但越来越多的证据表明,某些受体具有链中心性,即一个半 TCR 主导抗原识别并决定其特异性。目前,关于链中心性 TCR 的起源以及表达它们的功能性 T 细胞亚群,人们的了解还很有限。此外,α 和 β 链中心性 TCR 的比例以及天然库中链中心性 TCR 的精确比例,目前仍不清楚。在这篇综述中,我们对证明链中心性 TCR 的研究进行了回顾性分析,提出了它们产生的模式,并讨论了这些受体在 T 细胞基因修饰用于过继性癌症免疫治疗中的潜在应用。